	US 12,465,791 B2
	Oral care composition
Dandan Chen, Bridgewater, NJ (US); Harsh Mahendra Trivedi, Hillsborough, NJ (US); Peter R. Hilliard, Jr., Far Hills, NJ (US); and James Masters, Ringoes, NJ (US)
Assigned to Colgate-Palmolive Company, New York, NY (US)
Filed by Colgate-Palmolive Company, New York, NY (US)
Filed on Mar. 29, 2022, as Appl. No. 17/707,822.
Application 17/707,822 is a division of application No. 15/533,697, abandoned, previously published as PCT/US2015/066318, filed on Dec. 17, 2015.
Claims priority of provisional application 62/096,503, filed on Dec. 23, 2014.
Prior Publication US 2022/0219020 A1, Jul. 14, 2022
Int. Cl. A61Q 11/00 (2006.01); A61K 8/21 (2006.01); A61K 8/24 (2006.01); A61K 8/44 (2006.01)

CPC A61Q 11/00 (2013.01) [A61K 8/21 (2013.01); A61K 8/24 (2013.01); A61K 8/44 (2013.01)]

12 Claims

1. A method of increasing or accelerating HSP 27 expression in a tissue of an oral cavity comprising administering to the tissue a dentifrice composition comprising arginine or a salt thereof in an amount of 0.005 weight %, calcium carbonate in an amount of 20 weight % to 40 weight %, sodium lauryl sulfate, tetrasodium pyrophosphate in an amount of 0.1 weight %, and an orally acceptable carrier, wherein the dentifrice composition does not contain lysine, citrulline, ornithine, creatine, histidine, diaminobutanoic acid, or diaminopropionic acid, or a salt of lysine, citrulline, ornithine, creatine, histidine, diaminobutanoic acid, or diaminopropionic acid and wherein the weight % is by total weight of the composition.